Propanc Biopharma Advances PRP Production for Phase 1b Cancer Trial
Event summary
- Propanc Biopharma's CEO toured a European CDMO's GMP facility to prepare for PRP production for a Phase 1b, First-In-Human study in 30–40 advanced cancer patients.
- Preproduction is targeted for August 2026, with GMP manufacturing set to begin in December 2026.
- The CDMO operates a 4,500sqm facility with certifications including ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and GMP compliance.
- PRP is a novel combination of trypsinogen and chymotrypsinogen administered via IV injection once weekly.
The big picture
Propanc Biopharma's move to secure a European CDMO partner for PRP production underscores the critical role of specialized manufacturing capabilities in advancing novel cancer therapies. The strategic alignment with a facility equipped for biologics production highlights the growing trend of biopharmaceutical companies outsourcing complex manufacturing to accelerate clinical timelines. The success of this partnership could set a precedent for other early-stage developers targeting metastatic cancer.
What we're watching
- Regulatory Timelines
- Whether the stability data post-engineering run will be sufficient to support a Phase 1B clinical trial application in Australia in 2026.
- Manufacturing Execution
- The pace at which Propanc and the CDMO can advance PRP through clinical development, given the significant capital investment in modern equipment and facilities.
- Strategic Partnerships
- How the collaboration with the European CDMO will impact Propanc's ability to scale production and meet future clinical and commercial demands.